JPMorgan Increases Stake in Innovent Biologics to 5.08%

Summary

JPMorgan increased its stake in Innovent Biologics to 5.08% by purchasing 1.635942 million shares at HKD 90.9102 per share on November 24, 2025, totaling approximately HKD 149 million Zhitong.

Impact Analysis

So JPMorgan’s been steadily upping their stake in Innovent Biologics, now holding 5.08% after their latest buy on November 24 Zhitong. This isn’t just a one-off; they’ve been consistently adding shares over the past month Zhitong+ 2. The timing is interesting—right after Innovent’s inclusion in the Hang Seng Index and positive clinical trial results for their obesity drug Zhitong. This move suggests JPMorgan sees significant upside potential, likely betting on the stock’s re-rating as it transitions from a growth to a blue-chip asset QQ News. Technically, the stock’s in a medium-term uptrend with strong support around HKD 82 and resistance at HKD 94.30 . Given the bullish MACD crossover and the stock’s proximity to the upper Bollinger Band, there might be some short-term pressure, but the long-term outlook seems solid. Bottom line—JPMorgan’s confidence could drive further institutional interest, making this a stock to watch closely.